Literature DB >> 20494409

Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.

Patrick Mufarrij1, Alex Sankin, Guilherme Godoy, Herbert Lepor.   

Abstract

OBJECTIVES: To examine the pathologic findings and biochemical recurrence rates for a consecutive cohort of candidates for active surveillance who underwent radical prostatectomy. The role of active surveillance for the treatment of low-risk prostate cancer is highly controversial.
METHODS: Between October 2000 and February 2008, a single surgeon performed 1565 open radical retropubic prostatectomies for clinically localized prostate cancer. Cases were selected for extraction if they fulfilled 1 of 2 published criteria for active surveillance in our prospective longitudinal outcomes database. A retrospective review of the prospectively collected database was executed to elucidate the outcomes of candidates for active surveillance who underwent radical retropubic prostatectomy. Gleason score, pathologic stage, and surgical margins were prospectively captured in our database. The 5-year, biochemical-free survival rates were estimated using Kaplan-Meier analysis plots.
RESULTS: Overall, 45.9%-47.2% of cases were pathologically upgraded to a Gleason score ≥ 7. Moreover, 12.3%-13.1% of cases were found to have a primary Gleason pattern of 4 or 5. Extracapsular extension (pT3a disease) was observed in 7.8%-10.9% of cases. A total of 28.8%-32.2% of cases had an estimated percentage of cancer volume in the surgical specimen exceeding 20%. The 5-year biochemical-free survival was estimated to be 83.2%-92.9%.
CONCLUSIONS: Our pathologic findings and risk of biochemical recurrence after open radical prostatectomy questions the wisdom of active surveillance in men with low-risk disease who have "long" life expectancies.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20494409     DOI: 10.1016/j.urology.2009.12.075

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  28 in total

1.  Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance.

Authors:  Barry B McGuire; Brian T Helfand; Shilajit Kundu; Qiaoyan Hu; Jessica A Banks; Phillip Cooper; William J Catalona
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

Review 2.  Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data.

Authors:  Thomas A Dunn; Helen L Fedor; Angelo M De Marzo; Jun Luo
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

3.  The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml.

Authors:  Lorenzo Masieri; Andrea Minervini; Gianni Vittori; Michele Lanciotti; Federico Lanzi; Alberto Lapini; Marco Carini; Sergio Serni
Journal:  Int Urol Nephrol       Date:  2012-08       Impact factor: 2.370

Review 4.  Current trends and new frontiers in focal therapy for localized prostate cancer.

Authors:  Melissa H Mendez; Daniel Y Joh; Rajan Gupta; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2015-06       Impact factor: 3.092

5.  Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.

Authors:  Joan Alexander; Jude Kendall; Jean McIndoo; Linda Rodgers; Robert Aboukhalil; Dan Levy; Asya Stepansky; Guoli Sun; Lubomir Chobardjiev; Michael Riggs; Hilary Cox; Inessa Hakker; Dawid G Nowak; Juliana Laze; Elton Llukani; Abhishek Srivastava; Siobhan Gruschow; Shalini S Yadav; Brian Robinson; Gurinder Atwal; Lloyd C Trotman; Herbert Lepor; James Hicks; Michael Wigler; Alexander Krasnitz
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

6.  B-mode and acoustic radiation force impulse (ARFI) imaging of prostate zonal anatomy: comparison with 3T T2-weighted MR imaging.

Authors:  Mark L Palmeri; Zachary A Miller; Tyler J Glass; Kirema Garcia-Reyes; Rajan T Gupta; Stephen J Rosenzweig; Christopher Kauffman; Thomas J Polascik; Andrew Buck; Evan Kulbacki; John Madden; Samantha L Lipman; Ned C Rouze; Kathryn R Nightingale
Journal:  Ultrason Imaging       Date:  2014-07-23       Impact factor: 1.578

Review 7.  Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment.

Authors:  Marc A Bjurlin; Xiaosong Meng; Julien Le Nobin; James S Wysock; Herbert Lepor; Andrew B Rosenkrantz; Samir S Taneja
Journal:  J Urol       Date:  2014-04-21       Impact factor: 7.450

8.  Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.

Authors:  G I Russo; T Castelli; V Favilla; G Reale; D Urzì; S Privitera; E Fragalà; S Cimino; G Morgia
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-06-02       Impact factor: 5.554

Review 9.  Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

10.  Management of prostate cancer: NYU Case of the Month, July 2017.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.